Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000315066-25-002911
Filing Date
2025-11-07
Accepted
2025-11-07 11:13:45
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6882
2 exhibit99.txt EX-99 2929
  Complete submission text file 0000315066-25-002911.txt   11633
Mailing Address 245 SUMMER STREET BOSTON MA 02210
Business Address 245 SUMMER STREET BOSTON MA 02210 6175706339
FMR LLC (Filed by) CIK: 0000315066 (see all company filings)

EIN.: 043532603 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Subject) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89140 | Film No.: 251461152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)